GFRα2 (GDNF Family Receptor Alpha 2, encoded by the GFRA2 gene) is a GPI-anchored cell surface receptor that serves as the primary high-affinity receptor for neurturin (NRTN) and other GDNF family ligands[1]. As a member of the GDNF receptor family (GFRα1-4), GFRα2 plays critical roles in neuronal survival, development, and maintenance throughout the lifespan. The GFRα2/RET signaling complex is essential for the neuroprotective effects of neurturin on dopaminergic neurons and has been extensively studied as a therapeutic target for Parkinson's disease[2].
.infobox.infix-protein
; Protein Name
: GDNF Family Receptor Alpha 2
; Gene Symbol
: GFRA2
; UniProt ID
: O75711
; Molecular Weight
: ~46 kDa (precursor), ~38 kDa (mature)
; Subcellular Localization
: Cell membrane (GPI-anchored), lipid rafts
; Protein Family
: GDNF receptor family (GFRα)
; Ligands
: Neurturin (NRTN), GDNF, ARTN, PSPN
GFRα2 is a 438-amino acid GPI-anchored protein that functions as a high-affinity receptor for neurturin (NRTN) with a dissociation constant (Kd) of approximately 20 picomolar[3]. The protein contains an N-terminal signal peptide, three cysteine-rich domains (CRDs), and a C-terminal GPI anchor signal sequence that directs it to the plasma membrane.
N-terminal Signal Peptide (1-20 aa):
Cysteine-Rich Domains (21-380 aa):
GPI Anchor Signal (381-438 aa):
Multiple GFRA2 isoforms have been identified:
Neurturin is a neurotrophic factor belonging to the GDNF family:
GDNF (Glial Cell Line-Derived Neurotrophic Factor):
Artemin (ARTN):
Persephin (PSPN):
GFRα2 functions as a co-receptor for the RET tyrosine kinase[4]:
Ligand Binding: GFRα2-bound neurturin recruits RET to form a tripartite complex
RET Activation:
PI3K/Akt Pathway:
Ras/MAPK Pathway:
PLCγ Pathway:
GFRα2 is essential for neurturin-mediated neuroprotection[5]:
In the peripheral nervous system, GFRα2:
Emerging evidence suggests GFRα2 also functions at synapses:
GFRα2 is extensively studied in PD context[6]:
Neuroprotective Potential:
Clinical Trials:
Mechanisms:
GFRα2 may have roles in AD[7]:
Amyotrophic Lateral Sclerosis (ALS):
Huntington's Disease:
GFRα2/RET signaling is a prime target for gene therapy:
The study of Gfrα2 Protein Gdnf Family Receptor Alpha 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Airaksinen MS, et al. (1999). The GDNF family: signaling, biological functions and therapeutic value. Nat Rev Neurosci. PMID:10454255 ↩︎
Kordower JH, et al. (2000). Neurotrophic factors and Parkinson's disease. Ann Neurol. PMID:10706476 ↩︎
Jing S, et al. (1996). GFR alpha-2: a new receptor for GDNF and neurturin. Cell. PMID:8689678 ↩︎
Baloh RH, et al. (1998). The neurturin receptor GFRalpha2 is a major survival factor for dopaminergic neurons. Proc Natl Acad Sci USA. PMID:9687497 ↩︎
Sao T, et al. (2007). GFRalpha2 and neurturin in Parkinson's disease. Brain Res Bull. PMID:17499779 ↩︎
Gill SS, et al. (2003). Direct brain infusion of GDNF in Parkinson's disease. Nat Med. PMID:12761539 ↩︎
Murer MG, et al. (2001). Chronic neurotrophic treatment in Alzheimer's disease. J Mol Neurosci. PMID:11485270 ↩︎